Shares of Anthem Biosciences will be listed on the bourses today. After a successful IPO, the company has fixed the issue price at ₹570. According to the market buzz, the stock is likely to list with a gain of 20-25 per cent.
The initial public offering (IPO) of Bengaluru-based Anthem Biosciences Ltd (ABL) was subscribed 63.86 times, thanks to strong support from qualified institutional buyers (QIBs).
The ₹3,395-crore IPO was entirely an offer-for-sale (OFS) by promoters Ganesh Sambasivam and K Ravindra Chandrappa; investor shareholders Viridity Tone LLP and Portsmouth Technologies LLC; and other shareholders such as Malay J Barua, Rupesh N Kinekar, Satish Sharma, Prakash Kariabettan and K Ramakrishnan.
As against an offer for 4.40 crore shares, the IPO received bids for 281.44 crore shares.
While the QIB portion was subscribed 182.65 times, the quota reserved for retail investors and HNIs received bids for 5.64 times and 42.35 times, respectively. The portion reserved for employees (1.68 lakh shares) was subscribed 6.59 times.
ABL is an innovation-driven and technology-focused CRDMO with fully-integrated operations in Bengaluru, spanning across drug discovery, development and manufacturing.
Anchor investors
ABL raised ₹1,016 crore from anchor investors ahead of its initial share-sale opening for public subscription.
Some of the investors who participated in the anchor book were Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds and Societe Generale, HDFC Mutual Fund, ICICI Prudential MF, Axis MF, UTI MF, Quant MF and Motilal Oswal MF. It allotted 1.78 crore shares to 60 funds at ₹570 apiece.
Published on July 18, 2025
